Table 3. Non-serious adverse events.

Events	20 mg/kg/day PM for 21 days (N = 21)	15 mg/kg/day PM for 28 days (N = 21)
Diarrhea	1 (4.8%)	0
Injection site pain	14 (66.7%)	16 (76.2%)
Abnormal audiogram	3 (14.3%)	3 (14.3%)
Malaria	1 (4.8%)	1 (4.8%)
Acute otitis media	0	1 (4.8%)
PKDL	1 (4.8%)	4 (19.0%)
Epitaxis	0	1 (4.8%)
Cholestatic jaundice	0	1 (4.8%)
Jaundice	0	1 (4.8%)
Total	20	28

Data are n (%) of AEs reported. PKDL, Post-kala-azar dermal leishmaniasis.